An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A biotech company called Actimed Therapeutics says it has finished signing up participants for a small mid-stage clinical trial. The study, called PROACT Phase 2a, will test a drug named S-pindolol benzoate (ACM 001.1) in adults with obesity who are taking, or have been taking, semaglutide — the active drug in popular weight-loss medicines like Ozempic and Wegovy. The news is basically a recruitment update: the trial is ready to move forward now that people are enrolled. S-pindolol benzoate is the experimental substance being tested. The name sounds technical, but think of it as a drug candidate that researchers hope can help people keep weight off or improve outcomes when used around the time they take semaglutide. The report doesn’t give a simple mechanism, so we shouldn’t assume it works the same way as semaglutide (which mimics a gut hormone that reduces appetite and slows stomach emptying). ACM 001.1 is a different molecule being explored for its own potential benefits. The announcement only says recruitment is complete; it doesn’t report results. That means the study hasn’t yet published data showing whether S-pindolol benzoate helps people lose more weight, maintain weight loss, or avoid weight regain after stopping semaglutide. Because this is a Phase 2a trial, it’s an early study typically focused on safety and preliminary signs of benefit, often in a relatively small number of participants. We should expect any meaningful results to come later, after the company analyzes the trial data and shares the findings. Why does this matter to a regular person? Lots of people using semaglutide-based drugs struggle with weight returning when they stop the medication, or they want additional tools to improve long-term results. If ACM 001.1 helps people maintain weight loss or adds benefits during treatment, it could become an option alongside existing therapies. For anyone curious about weight-loss medicine trends, this trial shows researchers are still looking for complementary or follow-up treatments to semaglutide. There are important caveats. The trial is not proof that the drug works — it’s a step in testing. Early-phase studies can show promise but later fail to confirm benefits or reveal safety problems. Side effects, interactions with semaglutide, and long-term risks aren’t reported yet. Also, regulatory approval would require larger trials and review by authorities; being enrolled in a trial doesn’t mean the treatment is approved or widely available. People should not try to obtain or use experimental drugs outside regulated studies. Bottom line: Actimed has finished enrolling a small, early trial testing S-pindolol benzoate in people using semaglutide, but we’ll need to wait for trial results to know whether the drug is safe or effective.
Source: The Manila Times